These researchers applied the rhetorical concept of stasis to medical discourse by reviewing the FDA discussion on Avastin as a treatment for metastatic breast cancer. They concluded that the absence of stasis resulted in miscommunication between the interested parties. The FDA could have achieved stasis, these authors conclude, by first reaching consensus on the following questions: What counts as clinical benefit?